Bortezomib, cisplatin, and gemcitabine phase 1B study
Introduction
The ubiquitin-proteasome pathway plays a pivotal role in the degradation of most intracellular proteins in eukaryotic cells, including those regulating apoptosis, cell cycle progression, transcription factor activation and angiogenesis [Palombella et al., 1994; Read et al., 1995; King et al., 1996] . Bortezomib (VELCADE; Millennium Pharmaceuticals Inc, Cambridge, MA;
Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ), a dipeptide proteasome inhibitor, is a novel anti-neoplastic agent presently approved for the treatment of patients with relapsed and refractory multiple myeloma and relapsed mantle-cell lymphoma [Twombly, 2003] .
Inhibition of the chymotryptic-like proteolytic activity of the proteasome by bortezomib suppresses tumor survival through multiple mechanisms, including induction of G 2 -M phase cell cycle arrest, cleavage of bcl-2, upregulation and/or accumulation of BH3-only proteins, activation of caspases, and inhibition of nuclear factor-κB (NF-κB) activation [Beg and Baltimore, 1996; Ling et al., 2002; Adams, 2004; Fernandez et al., 2005; Perez-Galan et al., 2006] . In preclinical and clinical studies, it has shown a unique and promising cytotoxicity profile in a variety of solid tumors as well Ludwig et al., 2005] .
When the recommended schedule for multiple myeloma patients, twice-weekly administration of bortezomib 1.3 mg/m 2 , was administered as second-line treatment to non-small cell lung cancer (NSCLC) patients, 8% achieved a partial response [Richardson et al, 2005; Fanucchi et al, 2006] . Gemcitabine in combination with cisplatin is a widely used chemotherapeutic regimen for the treatment of advanced non-small cell lung cancer (NSCLC), urothelial cell cancer and other solid tumors [Sandler et al., 2000; Lehmann et al., 2003] . Preclinical and clinical studies indicate synergistic or additive activity when bortezomib is combined with gemcitabine and/or platinum agents [Teicher et al., 1999; Mortenson et al., 2004; Kamat et al., 2004; Aghajanian et al., 2005; Davies et al., 2006] . Inhibition of NF-κB activation, a factor thought to play a role in resistance to chemotherapy, and accumulation of proteins, misfolded or damaged by the effects of chemotherapy, might play important contributory roles [Imai et al., 2003; Fahy et al., 2005] . A sequence-specific interaction of bortezomib and several chemotherapeutics has been demonstrated in some preclinical studies, suggesting administration of chemotherapy prior to bortezomib increases apoptosis induction in cell lines, as compared to administrating chemotherapy after bortezomib administration [Mack et al., 2003; Mortenson et al., 2004] .
The present phase 1B study was designed to establish safety and maximum tolerated dose (MTD) of bortezomib in combination with cisplatin and gemcitabine in patients with advanced solid tumors, especially NSCLC, in order to determine a recommended phase 2 dose. Considering potentially overlapping toxicities between bortezomib and chemotherapy, and as an attempt to develop a more patient-friendly schedule, a weekly schedule of bortezomib was evaluated next to a twice-weekly schedule.
Patients and methods
Patients. Chemonaive adult patients with inoperable, locally advanced or metastatic cancer, for whom gemcitabine and cisplatin therapy was an acceptable therapeutic option, were eligible for this study. Tumors were cytologically or histologically confirmed.
Other eligibility criteria included: Karnofsky performance status (KPS) ≥ 70; life expectancy > 3 months; measurable or evaluable disease. An adequate method of birth control had to be used, and women of childbearing potential had to have a negative urine pregnancy test. Patients were excluded if they had received prior treatment with chemotherapy or bortezomib; had received treatment with monoclonal antibodies, other biologic therapies or investigational agents ≤ 4 weeks before enrollment; underwent major surgery ≤ 4 weeks before enrollment; underwent prior extensive radiation therapy (>25% of bone marrow reserve); underwent radiation therapy within 4 weeks prior to enrollment (except for limited radiation of bone metastases with 1-2 fractions); had inadequate bone marrow and/or organ function, defined as creatinine clearance <60mL/minute (calculated according to Cockcroft-Gault formula), total bilirubin ≥2 times the upper limits of normal, aspartate transaminase ≥3 times the upper limits of normal, alanine transaminase ≥3 times the upper limits of normal, hemoglobin ≤9.0 g/dL, platelet count <100× 10 9 /L, absolute neutrophils count <1.5 × 10 9 /L; had grade ≥ 2 peripheral neuropathy or grade ≥ 3 hearing loss as defined by NCI Common Terminology
Criteria for Adverse Events (NCI-CTCAE) version 3.0; had symptomatic central nervous system (CNS) metastases (corticosteroid use was allowed to suppress symptoms); were hypersensitive for boron or mannitol; had serious uncontrolled medical disease, active infection, significant cardiovascular disorder, or any psychiatric illness or other disorders that could potentially impair compliance. This study was reviewed and approved by the institutional review board of the study center. Informed consent was obtained from all patients before undergoing any study-related procedures. At least three patients were enrolled per dose level. Maximum tolerated dose (MTD) determination was based on occurrence of dose limiting toxicity (DLT) in cycle 1. DLT was defined as: any drug-related non-hematologic toxicity grade 3 or 4 (excluding nausea and vomiting or diarrhea responding to symptomatic management); grade 4 neutropenia lasting more than 5 days; grade 3 or 4 febrile neutropenia, grade 4 thrombocytopenia of any duration; and toxicity causing a delay in the start of the next cycle of more than 2 weeks. When a DLT was encountered, the cohort was expanded to six patients. Dose escalation was continued until a DLT was observed in two out of two to six patients.
Initially, doses of gemcitabine and cisplatin were reduced by 25% in case of grade 4 neutropenia and/or grade 3 thrombocytopenia or occurrence of any non-hematologic DLT in the previous cycle. In a protocol amendment the threshold for thrombocytopenia was lowered to grade 4. In case of a DLT in the previous cycle, bortezomib dose was reduced to the next lower dose level. If the patient was receiving 0.7 mg/m 2 , bortezomib was discontinued. Day 8 gemcitabine was reduced by 50% in case of neutrophils of 0.75-1.5x
case of neuropathy (cisplatin, bortezomib), nephrotoxicity (cisplatin) or ototoxicity (cisplatin).
Patients could receive a maximum of 6 cycles until disease progression, occurrence of an unacceptable adverse event (AE), death, or meeting of any criterion for withdrawal from treatment. When deemed beneficiary, patients were allowed to continue with bortezomib monotherapy for a maximum of one year. scan was conducted in subsequently enrolled patients at screening and end of treatment.
All adverse events were documented. Toxicity was assessed using the NCI-CTCAE, version 3.0. Patients were evaluated for response using the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines at screening, every two cycles, at end of treatment and at 6-weeks follow-up [Therasse et al, 2000 ]. An objective response was to be confirmed after at least 6 weeks. Patients were observed for disease and survival assessment until death.
Blood sampling and pharmacokinetic analysis. At the MTD, blood plasma samples were drawn from 12 patients (6 patients in each group) for determination of total platinum, gemcitabine, dFdC (2',2'-difluoro-2'-deoxycytidine, gemcitabine), its metabolite dFdU (2',2'-difluoro-2'-deoxyuridine), and endogenous deoxycytidine (CdR) at the following time points: cycle 1, day 1, before infusion of gemcitabine, at the end of gemcitabine infusion, just before starting the cisplatin infusion, and at 30, 60, 120, and 180 minutes after cisplatin infusion and 24 hours after gemcitabine infusion; day 8, before infusion of gemcitabine, at the end of gemcitabine infusion, and at 30 minutes after gemcitabine infusion. Processing of samples and determination of compounds were as described previously [van Moorsel et al., 1999; Honeywell et al., 2006; Honeywell et al., 2007] . Briefly, 150 μL of plasma was extracted and stored at −20°C until analysis.
Separation and quantification of gemcitabine and dFdU from the plasma was achieved with an isocratic reversed-phase high-performance liquid chromatography (HPLC) system using a μBondapak C18 column. Peak areas were quantified using the data acquisition program Chromeleon (version 3.02; Chromeleon Chromatography Data Systems, Gynkotek HPLC, Germering, Germany). For CdR measurement, plasma extracts were prepared by protein precipitation and an ethyl acetate/water back extraction.
Quantitation was performed by multi-reaction monitoring (MRM) tandem mass spectrometry, using 15 N 3 CdR as an isotopic internal standard. For total plasma platinum (Pt) samples were diluted ten times with 0.38 M NaCl/0.5 M HCL and 0.2% triton + 0.2% antifoam prior to measurement by flameless atomic absorption spectrophotometry (spectra AA−300 Zeeman AAS Varian, Houten, The Netherlands).
Statistical analysis. Descriptive statistics were used for baseline characteristics, safety assessment, and pharmacokinetic data. The response rate was calculated for all response-evaluable patients along with the 95% confidence interval (CI). Median duration of response, stable disease, progression free survival and overall survival was calculated using the Kaplan-Meier method, along with their 95% CI.
Results
Patients and treatment. A total of 34 chemonaive patients were enrolled between August 2004 and June 2005. All patients were included in the safety and efficacy analyses and received at least one dose of study drug. Table 1 shows patient baseline characteristics. Most patients (n = 27) had NSCLC.
Twenty-six out of 27 NSCLC patients (96%) were current or former smokers and 4 patients (15%) had received prior treatment with erlotinib.
Twenty-seven patients (79%) had metastatic disease, 10 of whom with involvement of the CNS (37%). At study entry, one patient was diagnosed with adenocarcinoma of unknown primary, which was later diagnosed as breast carcinoma. Thirty-four patients received a total of 142 cycles. In total Reasons for dose reduction were thrombocytopenia (38%), neutropenia (37%), neutropenia combined with thrombocytopenia (10%), asthenia (8%), ototoxicity (3%) and other (5%). Comparing patients receiving weekly and twice-weekly bortezomib 1.0 mg/m 2 reasons for dose reduction were: neutropenia, 60% vs. 53%; thrombocytopenia 6% vs. 37%; combined neutropenia and thrombocytopenia, 0% vs. 5%. In the weekly schedule of bortezomib 1.3 mg/m 2 reasons for dose reduction were thrombocytopenia 29%, combined neutropenia and thrombocytopenia 29%, neutropenia 18%, and asthenia 24%. In 41% of patients, start of one or more treatment cycles was delayed due to toxicity. Delays were caused by neutropenia (75%) or non-hematologic toxicity (25%).
Common treatment-related AEs occurring throughout the trial are shown in Table 3 and included asthenia (100%), nausea (91%), taste alteration (82%), anorexia (79%), constipation (79%), tinnitus (71%) and sensory neuropathy (62%). Weekly bortezomib 1.0 mg/m 2 was generally better tolerated than twice-weekly 1.0 mg/m 2 treatment. We observed a trend towards higher incidence of (severe) myelotoxicity as well as gastro-intestinal toxicity and asthenia with increased dose-intensity of bortezomib. Due to grade 3 gastrointestinal toxicity, 1 (8%) and 3 (25%) patients treated with bortezomib 1.0 mg/m 2 weekly or twice-weekly, respectively, were treated with aprepitant. For anemia treatment or prophylaxis, 17 (50%) of patients received (darb)epoetin. Three patients (9%) repeatedly experiencing neutropenia received pegfilgrastim injections. Sixteen (47%) of patients developed a lowgrade rash, which was typically acneiform. Fifteen (44%) patients experienced facial/ peri-orbital edema. One patient, who was being treated with gemcitabine and bortezomib only, after discontinuation of cisplatin due to asthenia and gastro-intestinal toxicity, experienced severe, grade 3 peri-gemcitabine only.
Results of additional assesments of neuro-, oto-, nephro-, and cardiotoxicity are listed in Two patients experienced grade 4 non-hematologic toxicity. One NSCLC patient, who was being treated with corticosteroids because of CNS metastases, had a gastric perforation from which she recovered without surgical intervention. Another patient, who had a partial response, presented with acute abdominal pain. Explorative laparotomy showed a large intraabdominal collection of pus without signs of gastro-intestinal perforation at that time.
One NSCLC patient died during treatment. A bronchial stent placed before start of chemotherapy had migrated, most probably due to tumor shrinkage.
During an endoscopic replacement procedure an acute fatal pulmonary hemorrhage occurred.
Tumor response. All enrolled patients were evaluable for response. As shown in Table 5 , overall response rate was 38% (95% CI, 21-55%). Response rate in NSCLC patients combining all dose groups and both treatment schedules was 33% (95% CI, 15-51%). In NSCLC patients, twice-weekly administration of bortezomib resulted in a response rate of 25% (95% CI, 0-50 %) compared to 40% (95% CI, 15-65 %) in patients who received weekly administration of bortezomib. Disease control rate (responses plus stable disease) in NSCLC patients was 89% with a median stable disease duration of 3.0 months (95% CI, 2.0-4.0 months) and median response duration of 5.6 months (95% CI, 4.1-7.1 months). Of 4 patients with urothelial cell cancer, three had a partial response. Only one patient, with pancreatic cancer, who experienced stable disease after 6 cycles of therapy, opted to continue on monotherapy bortezomib, which was discontinued after two cycles due to progressive disease. No other responding patients or patients with stable disease opted to continue with bortezomib monotherapy. In patients with progressive disease we observed an average weight loss of 6% at end of treatment compared to 2% in patients with stable disease and a weight gain of 2% in patients responding to treatment.
As the study population constituted a heterogenous group of patients with various solid tumor types, we performed a subgroup analysis for time to progression and survival in NSCLC patients (n =27) only. In an intention to treat analysis, median follow up was 19 months. One NSCLC patient was lost to follow-up at 7 months due to emigration. As shown in Figure 2 , median overall survival (OS) and time to progression (TTP) were 315 days (95% CI 206-424 days; 6 patients censored) (10.4 months) and 152 days (95% CI 101-203 days; 1 patient censored) (5.0 months), respectively. The 1-year survival probability for NSCLC patients was 41%. In patients treated with bortezomib twice-weekly (n = 12) median survival and TTP were 299 days (95% CI 90-508 days; 4 patients censored) (9.8 months) and 120 days (95% CI 110-130 days; 1 patient censored) (3.9 months), respectively. In patients Pharmacokinetic analysis. Table 6 and Figure 3 show the plasma pharmacokinetic parameters for cisplatin (platinum) and gemcitabine (dFdC and gemcitabine's inactive metabolite dFdU). Addition of bortezomib did not seem to alter these parameters compared to historical controls generated in our laboratory (van Moorsel et al, 1999; Kroep et al, 2006] . In addition to measurements of the deoxycytidine-analog gemcitabine, the plasma level of endogenous deoxycytidine (CdR) was also determined. We observed an unexpected, transient drop in the level of plasma CdR in the current combination of bortezomib, gemcitabine and cisplatin.
Discussion
Bortezomib is a novel and promising anti-neoplastic agent, presently approved for the treatment of second-line multiple myeloma and mantle-cell lymphoma patients. Many studies are being conducted in solid tumor patients and as a single agent bortezomib has shown modest activity in NSCLC patients [Fanucchi et al., 2006] . As inhibition of proteasome activity might sensitize for chemotherapy-induced cytoxicity, combinations of bortezomib and chemotherapy are being investigated [Scagliotti et al., 2006) .
In this study we combined bortezomib and cisplatin-gemcitabine ) alone [Scagliotti et al., 2002; Zatloukal et al., 2003] . However, the cause and kinetics of bortezomibinduced thrombocytopenia differ from conventional chemotherapy-induced thrombocytopenia. Bortezomib-induced thrombocytopenia is due to a reversible effect on megakaryocytic function rather than a direct cytotoxic effect on megakaryocytes. Consequently, bortezomib-induced thrombocytopenia is characterized by rapid recovery during the wash-out period and is associated with a low incidence of bleeding, which was also our experience in the combination with cisplatin and gemcitabine [Lonial et al., 2005] .
Surprisingly, combining cisplatin and bortezomib, we did not observe treatment-emergent neuropathy, though the majority of patients experienced low-grade neuropathy. Refractory multiple myeloma patients treated with twice-weekly bortezomib 1.0 mg/m 2 were reported to have a 21% incidence of treatment-emergent neuropathy [Richardson et al., 2006] . This might be due to the fact that patients in our study were not pretreated with neurotoxic drugs, patients with ≥ grade 2 neuropathy were excluded and, in multiple myeloma patients, paraproteinemic associated neuropathy might contribute to the relatively high incidence of observed neuropathy [Ropper et al., 1998 ].
Neutropenia was the primary cause of treatment delay. Three patients (9%) experienced repeatedly prolonged neutropenia, causing unacceptable treatment delay. Growth factor support with G-CSF injections was effective in preventing persisting neutropenia in these patients and could therefore be considered in patients experiencing prolonged neutropenia following the first treatment cycle. We do not recommend standard use of G-CSF injections with this combination treatment as these patients formed a small subgroup of the total study population.
Plasma pharmacokinetic parameters of cisplatin and gemcitabine were not affected by the addition of bortezomib. As the effectiveness of deoxycytidine (CdR) analogs, such as gemcitabine, can be linked to the direct competition with active forms of endogenous CdR, we also determined the plasma level of endogenous deoxycytidine in patient samples [Honeywell et al., 2006] .
Endogenous deoxycytidine plasma levels showed an unexpected, transient drop. This was not observed in other patients treated with cisplatingemcitabine in our hospital (data not shown). The significance of this finding, notably if there might be an effect of bortezomib co-administration on intracellular gemcitabine metabolism, is unclear and is currently being investigated.
A recently published phase 1 study reported that the inhibition of 20S proteasome activity in PBMCs by bortezomib was unaffected by gemcitabine coadministration [Ryan et al., 2006] . As for pharmacodynamic activity of bortezomib in combination with gemcitabine and cisplatin, a pilot experiment, measuring proteasome activity in a few remaining PBMC samples, showed a decrease in proteasome activity upon treatment [Lightcap et al., 2000 ].
Furthermore we observed throughout the study population a typical bortezomib-associated cyclical thrombocytopenia pattern whilst on treatment.
The achieved overall response rate in NSCLC patients in our study is 33%.
Notably, as much as 10 (37%) of our 27 NSCLC patients presented with brain metastases, 4 patients (15%) using corticosteroids at study entry and 2 additional patients (7%), early progressive on treatment, started shortly after study entry with corticosteroids. The response rate appears to be similar to those observed in advanced NSCLC patients treated with only cisplatin and gemcitabine, generally at higher doses of up to 80 mg/m 2 and up to 1,250 mg/m 2 , respectively [Cardenal et al., 1999; Sandler et al., 2000; Scagliotti et al., 2002; Zatloukal et al., 2003; Mazzanti et al., 2003; Gebbia et al., 2003] .
Although this study was not powered to show a difference between the two schedules, response rates were similar in the weekly regimen compared to the twice-weekly regimen and overall survival as well as progression free survival curves seemingly superimposable.
Recently, final results were presented from a phase 2 study in which efficacy of bortezomib twice-weekly 1.0 mg/m 2 , carboplatin AUC 5 and gemcitabine 1,000 mg/m 2 , was assessed in 114 chemonaive stage advanced NSCLC patients [Davies et al., 2006] . At a median follow-up of 13 months PFS and OS were 5 and 11 months, respectively. The 11-month median survival achieved was regarded as unprecedented by the authors. In that trial chemotherapy was administered prior to bortezomib, based on preclinical results indicating this sequence might favor efficacy [Mack et al., 2003; Mortenson et al., 2004] . In our trial we administered chemotherapy after bortezomib, achieving comparable PFS and median OS duration in advanced NSCLC patients. Furthermore, a weekly schedule of bortezomib in combination with carboplatin and gemcitabine was not investigated by Davies et al. [Davies et al, 2006] , nor were pharmacokinetic variables for gemcitabine or carboplatin determined. Interestingly, a weekly administration of bortezomib is currently being studied as a more convenient alternative in multiple myeloma and non-Hodgkin lymphoma as well [Greco et al., 2006; Suvannasankha et al., 2006] .
In conclusion, bortezomib can be safely combined with cisplatin-gemcitabine chemotherapy and constitutes an active regimen in advanced stage NSCLC patients. Though this is a non-randomized, phase 1 study does not allow comparison between the two schedules, the weekly schedule of bortezomib appears to be favorable over a twice-weekly schedule, based on lower toxicity and no indication of inferior activity compared to the twice-weekly schedule.
